EXPRESSION OF MARKERS OF APOPTOSIS (P53, BCL-2, BAX) AND PROLIFERATION (KI-67, TOPOISOMERASE IIA, ARGYROPHILIC PROTEINS OF NUCLEOLAR ORGANIZER REGIONS) IN HEALTHY PERSONS AND NON-SMALL CELL LUNG CANCER PATIENTS AND THEIR RELATIONSHIP WITH SOME CLINICAL AND MORPHOLOGICAL PARAMETERS

Abstract

Study of markers of apoptosis and proliferation in relation to clinical and morphological parameters in non-small cell cancer (NSCLC) patients and healthy persons. There were investigated 237 surgery samples of NSCLC and 10 cases of normal lung tissues. p53, bcl-2, bax, Ki-67, topoisomerase IIα (ТороIIα) levels were determined by immunohistochemical method. Argyrophilic proteins associated with nucleolar organizer regions (AgNOR) were detected with silver nitrate. In NSCLC expression of p53, bcl-2, Ki-67, TopoIIα, AgNOR increased and expression of bax was lower if compared with the normal tissue. Expression of apoptotic markers (p53, bcl-2, bax) correlated with clinical and morphological parameters of NSCLC: histogenesis, N index and the stage (for bcl-2), gender (for bax). Expression of Ki-67 and TopoIIα correlated with gender, largest size of the tumor, histogenesis and differentiation. AgNOR proteins were interrelated with the gender, T and N indices, largest tumor dimension, stage, histogenesis and differentiation. In NSCLC cases the expression of apoptotic markers correlated with proliferation: in p53 positive tumors - high level of proliferation (Ki-67, TopoIIα, AgNOR), in bcl-2 positive tumors - low AgNOR, in bax positive tumors - low proliferative activity (Ki-67, TopoIIα). In NSCLC there is observed the change in expression of apoptotic markers (p53, bcl-2, bax) and proliferation (Ki-67, TopoIIα, AgNOR) in conjunction with normal tissue and clinical and morphological parameters of tumor.

Keywords

proliferation / apoptosis / non-small cell lung cancer

References

[1] Коган Е.А., Швец С.И., Коваленко В.Л., Соболева Ю.В. Соотношение процессов пролиферации, апоптоза, ангиогенеза и метастазирования в различных гистогенетических типах рака легкого (иммуногистохимическое исследование). Арх. патол. 2004; 66(6): 33-8.

[2] Carvalho P.E., Antonangelo L., Bernardi F.D., Leao L.E., Rodrigues O.R., Capelozzi V.L. Useful prognostic panel markers to express the biological tumor status in resected lung adenocarcinomas. J. Clin. Oncol. 2000; 30(11): 478-86.

[3] Groeger A.M., Esposito V., De Luca A., Cassandro R., Tonini G., Ambrogi V. et al. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology. 2004; 44(1): 54-63.

[4] Jeanmart M., Lantuejoul S., Fievet F., Moro D., Sturm N., Brambilla C. et al. Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. Clin. Cancer Res. 2003; 9(6): 2195-203.

[5] Lai R.S., Wang J.S., Hsu H.K., Chang H.C., Lin C.H., Lin M.H. Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer. Jpn. J. Clin. Oncol. 2002; 32(10): 393-7.

[6] Ohmura Y., Aoe M., Andou A., Shimizu N. Telomerase activity and Bcl-2 expression in non-small cell lung cancer. Clin. Cancer Res. 2000; 6(8): 2980-7.

[7] Poleri C., Morero J.L., Nieva B., Vazquez M.F., Rodriguez C., de Titto E. et al. Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis. Chest. 2003; 123(6): 1858-67.

[8] Porebska I., Wyrodek E., Kosacka M., Adamiak J., Jankowska R., Harlozinska-Szmyrka A. Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer. In Vivo. 2006; 20(5): 599-604.

[9] Rodrigues O.R., Antonangelo L., Yagi N., Minamoto H., Schmidt Júnior A.F., Capelozzi V.L. et al. Prognostic significance of argyrophilic nucleolar organizer region (AgNOR) in resected non-small cell lung cancer (NSCLC). Jpn. J. Clin. Oncol. 1997; 27(5): 298-304.

[10] Sobin L., Gospodarowicz M., Wittekind C. TNM Classification of Malignant Tumours. 7th Ed. Oxford, Wiley-Blackwell. 2009: 138-46.

[11] Trere D. AgNOR staining and quantification. Micron. 2000; 31(2): 127-31.

[12] Derenzini M., Trere D. Standardization of interphase Ag-NOR measurement by means of an automated image analysis system using lymphocytes as an internal control. J. Pathol. 1991; 165(4): 337-42.

[13] Лазарев А.Ф., Бобров И.П., Климачев В.В., Лубенников В.А. Характеристика ядрышкового аппарата опухолевых клеток при раке желудка. Арх. патол. 2002; 64(6): 30-2.

[14] Лазарев А.Ф., Кобяков Д.С., Климачев В.В., Авдалян А.М., Бобров И.П. Аргирофильные белки районов ядрышковых организаторов в аденомах с различной степенью дисплазии и аденокарциноме толстой кишки. Арх. патол. 2010; 72(4): 16-20.

[15] D’Amico T.A., Aloia T.A., Moore M.B.H., Herndon J.E., Brooks K.R., Lau C.L. et al. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann. Thorac. Surg.2000; 69(6): 882-6.

RIGHTS & PERMISSIONS

Eco-Vector